Velzatinib (IDRX-42, GSK6042981)
Sources
publication, as of 2026-11-07
https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11501
In 2L pts, median follow-up (mFU) was 14.7 ... mo and median progression-free survival (mPFS) was 13.7 (95% CI: 7.4, 18.4) mo. In 1L ... 11 (61%) experienced unconfirmed responses ... 2L total (n=46) Objective response rate 16 (35)
J Clin Oncol 44(16_suppl) abstract 11501 (ASCO 2026), StrateGIST 1 (NCT05489237); congress abstract, preliminary
publication, as of 2026-11-07
https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS11588
Approximately 450 pts will be randomized (1:1) to receive either velzatinib (300-mg QD tablet, continuous dosing) or sunitinib (50 mg QD, 4 weeks on/2 weeks off) ... will be excluded if they have GIST that is wild type for both KIT and PDGFRA or if they have an activating PDGFRA exon 18 mutation
J Clin Oncol 44(16_suppl) TPS11588 (ASCO 2026)
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05489237
A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07218926
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07585266
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07